棕榈酸帕利哌酮注射液维持治疗精神分裂症15例观察

doi:10.3969/j.issn.1004-583X.2026.10.007

摘要/Abstract

摘要：

目的观察棕榈酸帕利哌酮长效注射剂维持治疗期间精神分裂症患者的症状与社会功能变化。方法整理2022年8月-2026年9月山东省戴庄医院15例患者病例报告表,比较基线及末次随访PANSS、CGI-S、PSP评分。结果随访中位数366 d;PANSS总分由72分降至41分,CGI-S由5分降至3分,PSP由55分升至78分(均P<0.01)。结论本组症状与功能评分总体改善,但无对照设计不能支持因果推断。

关键词: 精神分裂症, 棕榈酸帕利哌酮, 长效注射剂, 社会功能, 病例系列

Abstract:

Objective To observe changes in symptoms and social functioning of patients with schizophrenia during maintenance treatment with paliperidone palmitate long-acting injection. Methods Case report forms of 15 patients who were treated at Shandong Daizhuang Hospital from February 2022 to January 2026 were reviewed. Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S), and Personal and Social Performance (PSP) scores were compared at baseline and at the last follow-up. Results The median follow-up duration was 366 days. PANSS total score decreased from 72 to 41, CGI-S decreased from 5 to 3, and PSP increased from 55 to 78 (all P<0.01). Conclusion Overall, symptom and functional scores improved in this group; however, the lack of a controlled design precludes causal inference.

Key words: schizophrenia, paliperidone palmitate, long-acting injectable, social functioning, case series

中图分类号:

R749.3

王战, 宋海宁, 高岭楠, 姜卓, 张程皓, 李润泽, 王中刚. 棕榈酸帕利哌酮注射液维持治疗精神分裂症15例观察[J]. 临床荟萃, 2026, 41(10): 916-921.

Wang Zhan, Song Haining, Gao Lingnan, Jiang Zhuo, Zhang Chenghao, Li Runze, Wang Zhonggang. Observation of paliperidone palmitate injection maintenance treatment in 15 patients with schizophrenia[J]. Clinical Focus, 2026, 41(10): 916-921.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.10.007

https://www.lchc.cn/CN/Y2026/V41/I10/916

图/表 2

参考文献 26

[1]	Li P, Geng Z, Benson C, et al. Real-world effectiveness of long-acting injectable and oral antipsychotic agents in US medicare patients with schizophrenia[J]. Adv Ther, 2025, 42(2): 1251-1264. doi: 10.1007/s12325-024-03075-6.
[2]	Boyer L, Falissard B, Nuss P, et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12, 373 patients with schizophrenia-spectrum disorders[J]. Mol Psychiatry, 2023, 28(9): 3709-3716. doi: 10.1038/s41380-023-02175-z.
[3]	庄晓勇, 江坤鸿, 孙启美, 等. 奥氮平联合利培酮治疗精神分裂症患者阴性症状及社会功能的临床观察[J]. 临床荟萃, 2025, 40(11): 1012-1015. doi: 10.3969/j.issn.1004-583X.2025.11.007.
[4]	马晓亮, 王凯婷. 奥氮平联合计算机认知矫正对精神分裂症患者的疗效[J]. 临床荟萃, 2025, 40(12): 1098-1103. doi: 10.3969/j.issn.1004-583X.2025.12.008.
[5]	伍周文, 何欣怡. 文体训练对康复期精神分裂症患者应对方式和生活质量的影响[J]. 临床荟萃, 2024, 39(12): 1085-1088. doi: 10.3969/j.issn.1004-583X.2024.12.004.
[6]	Zhou Y, Chen B, Huang Y. Healthcare utilization and economics evaluation of paliperidone palmitate once-monthly in schizophrenia: A one-year, real-world, and retrospective mirror image study in China[J]. Front Psychiatry, 2024, 15: 1415275. doi: 10.3389/fpsyt.2024.1415275.
[7]	Gou L, Su R, Guo R, et al. Efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) for schizophrenia in southwestern China[J]. BMC Psychiatry, 2025, 25(1): 342. doi: 10.1186/s12888-025-06646-1. pmid: 40200201
[8]	Dong L, Liu XY, Chen WC, et al. Efficacy of paliperidone palmitate once-monthly (PP1M) in improving social functioning and reducing caregiver burden in patients with schizophrenia: A six-month follow-up study[J]. BMC Psychiatry, 2025, 25(1): 730. doi: 10.1186/s12888-025-07155-x. pmid: 40730966
[9]	Lin CH, Chiang CL, Yu DY, et al. Clinical remission, functional recovery, and employment in early-phase schizophrenia treated with paliperidone palmitate: An 18-month longitudinal Asia-Pacific study[J]. Psychiatry Res, 2026, 358: 116955. doi: 10.1016/j.psychres.2026.116955.
[10]	Huang Y, Zhang J, Ling J, et al. Comparative efficacy of oral and long-acting injectable paliperidone on social functioning in schizophrenia: A systematic review and meta-analysis[J]. Schizophr Res, 2026, 295: 212-225. doi: 10.1016/j.schres.2026.06.013.
[11]	Oh J, Oh J, Kim DW, et al. Effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social performance of patients with schizophrenia[J]. Clin PsychopharmacolNeurosci, 2023, 21(1): 126-134. doi: 10.9758/cpn.2023.21.1.126.
[12]	Sajatovic M, Doring M, Lopena OJ, et al. Earlier use of long-acting injectable paliperidone palmitate once-monthly versus oral antipsychotics in patients with schizophrenia: An integrated patient-level meta analysis of the PROSIPAL and PRIDE studies[J]. Neuropsychiatr Dis Treat, 2024, 20: 2227-2235. doi: 10.2147/NDT.S427227.
[13]	Li X, Ye C, Zhang W, et al. Factors associated with symptom stabilization that allow for successful transition from once-monthly paliperidone palmitate to three-monthly paliperidone palmitate: A post hoc analysis examined clinical characteristics in Chinese patients with schizophrenia[J]. CNS Drugs, 2024, 38(1): 55-65. doi: 10.1007/s40263-023-01056-x. pmid: 38190077
[14]	Okada Y, Inada K, Akazawa M. Comparative effectiveness of long-acting injectable versus oral antipsychotics in patients with schizophrenia using the prevalent new user design and subgroup analyses[J]. J Clin Psychopharmacol, 2024, 44(3): 263-271. doi: 10.1097/JCP.0000000000001841. pmid: 38684048
[15]	Vita G, Tavella A, Ostuzzi G, et al. Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: A systematic review and meta-analysis[J]. Ther Adv Psychopharmacol, 2024, 14: 20451253241257062. doi: 10.1177/20451253241257062.
[16]	Wang D, Schneider-Thoma J, Siafis S, et al. Efficacy, acceptability and side-effects of oral versus long-acting-injectables antipsychotics: Systematic review and network meta-analysis[J]. EurNeuropsychopharmacol, 2024, 83: 11-18. doi: 10.1016/j.euroneuro.2024.03.003.
[17]	Uribe ES, Mundo SEO, Garza RRM, et al. Comparative safety of long-acting injectable antipsychotics: A systematic review and network meta-analysis[J]. Psychiatry Investig, 2023, 20(12): 1112-1125. doi: 10.30773/pi.2022.0216.
[18]	Bui TNT, Au RT, Janetzki JL, et al. Metabolic monitoring for adults living with a serious mental illness on a second-generation antipsychotic agent: A scoping review[J]. Adm Policy Ment Health, 2025, 52(2): 289-317. doi: 10.1007/s10488-024-01408-9.
[19]	卢远思, 吕见君, 官计彬, 等. 双相情感障碍患者外周血中FGF1的表达与糖脂代谢的相关性[J]. 临床荟萃, 2025, 40(7): 619-623. doi: 10.3969/j.issn.1004-583X.2025.07.006.
[20]	孙振晓, 于相芬. 奥氮平致外周水肿1例并文献复习[J]. 临床荟萃, 2025, 40(9): 833-836. doi: 10.3969/j.issn.1004-583X.2025.09.010.
[21]	Castle D, Li A. Physical health monitoring for people with schizophrenia[J]. Aust Prescr, 2023, 46(4): 75-79. doi: 10.18773/austprescr.2023.024. pmid: 38152317
[22]	Shin S, Moon S, Wang J, et al. Impact of institutional quality improvement initiatives on metabolic monitoring in mental disorder in patients treated with antipsychotics: A meta-analysis of intervention studies[J]. J Glob Health, 2024, 14: 04074. doi: 10.7189/jogh.14.04074. pmid: 38783701
[23]	Aymerich C, Salazar de Pablo G, Pacho M, et al. All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis[J]. Mol Psychiatry, 2025, 30(1): 263-271. doi: 10.1038/s41380-024-02694-3.
[24]	Arango C, Fagiolini A, Gorwood P, et al. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery[J]. BMC Psychiatry, 2023, 23(1): 453. doi: 10.1186/s12888-023-04928-0. pmid: 37344763
[25]	Correll CU, Johnston K, Turkoz I, et al. Three-year outcomes of 6-month paliperidone palmitate in adults with schizophrenia: An open-label extension study of a randomized clinical trial[J]. JAMA Netw Open, 2024, 7(7): e2421495. doi: 10.1001/jamanetworkopen.2024.21495.
[26]	Najarian D, Turkoz I, Knight RK, et al. Long-term efficacy and safety of paliperidone 6-month formulation: An open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia[J]. Int J Neuropsychopharmacol, 2023, 26(8): 537-544. doi: 10.1093/ijnp/pyad028. pmid: 37480362

指标	基线	末次随访	P值
PANSS总分	72(60,83)	41(37,46)	<0.01
阳性症状	15(11.5,19.5)	8(7,9)	<0.01
阴性症状	20(14.5,21)	12(11,14)	<0.01
一般精神病理	36(31.5,42)	20(19,21.5)	<0.01
CGI-S	5(4,5)	3(2,3)	<0.01
PSP	55(45,61.5)	78(75,80)	<0.01

指标	基线	末次随访	P值
PANSS总分	72(60,83)	41(37,46)	<0.01
阳性症状	15(11.5,19.5)	8(7,9)	<0.01
阴性症状	20(14.5,21)	12(11,14)	<0.01
一般精神病理	36(31.5,42)	20(19,21.5)	<0.01
CGI-S	5(4,5)	3(2,3)	<0.01
PSP	55(45,61.5)	78(75,80)	<0.01

编号	随访(d)	PANSS总分(分)	PSP(分)
01	307	69→37	45→75
02	738	85→48	58→75
03	308	72→37	42→75
04	368	117→62	55→76
05	307	65→55	55→60
06	367	103→37	35→78
07	392	53→40	65→85
08	308	43→44	75→74
09	368	97→38	35→80
10	187	59→43	58→80
11	367	61→41	65→80
12	368	40→33	80→90
13	362	81→51	55→78
14	366	75→41	55→82
15	188	81→34	45→80

编号	随访(d)	PANSS总分(分)	PSP(分)
01	307	69→37	45→75
02	738	85→48	58→75
03	308	72→37	42→75
04	368	117→62	55→76
05	307	65→55	55→60
06	367	103→37	35→78
07	392	53→40	65→85
08	308	43→44	75→74
09	368	97→38	35→80
10	187	59→43	58→80
11	367	61→41	65→80
12	368	40→33	80→90
13	362	81→51	55→78
14	366	75→41	55→82
15	188	81→34	45→80